TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for **B‑cell–mediated diseases**, with a primary emphasis on multiple sclerosis and hematologic... TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for **B‑cell–mediated diseases**, with a primary emphasis on multiple sclerosis and hematologic conditions. Its lead product, BRIUMVI (ublituximab‑xiiy), is an anti‑CD20 monoclonal antibody indicated for relapsing forms of multiple sclerosis, addressing a key segment of the neurology market where efficacy, infusion profile, and safety are central considerations. The company’s revenue base has increasingly centered on BRIUMVI’s U.S. uptake, reflecting its strategic transition from development to commercial execution and providing a recurring product revenue foundation. TG Therapeutics operates within the broader pharmaceuticals sector and is tracked on international venues including the Italian market under a global equity listing framework, with third‑party services providing pricing, market data, and coverage for investors and analysts. Its positioning highlights the role of targeted B‑cell therapies in autoimmune disease management, and its activities contribute to innovation pipelines and competitive dynamics among neurologic and immunology therapeutics developers.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Energy Management data not yet covered for TG Therapeutics

We have not yet reviewed TG Therapeutics's disclosures for Energy Management data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review TG Therapeutics's data?

Create a free Tracenable account to signal interest in having our team review data for TG Therapeutics.

Legal Center Contact Us